ALKEM2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2019-10-012019-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2019-10-012019-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2019-04-01 2020-03-31 2020-01-29 INR Millions Third quarter Single segment The Company is exclusively engaged in pharmaceutical business 2019-10-01 2019-12-31 Unaudited Consolidated 21818400000.00 278600000.00 22097000000.00 5494200000.00 3834300000.00 -984200000.00 3956200000.00 170400000.00 594800000.00 4985200000.00 18050900000.00 4046100000.00 0.00 4046100000.00 387400000.00 -240900000.00 146500000.00 0.00 3899600000.00 0.00 0.00 0.00 0.00 3899600000.00 107900000.00 4007500000.00 3819800000.00 79800000.00 3930300000.00 77200000.00 239100000.00 2 31.95 31.95 0.00 0.00 31.95 31.95 1) The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 6 February 2020 and subsequently approved by the Board of Directors at its meeting held on 7 February 2020. The figures for the quarter and nine months ended 31 December 2019 have been subjected to limited review by the statutory auditors. The auditors have expressed an unmodified opinion on the financial results for the quarter and nine months ended 31 December 2019. n n2) Effective 1 April 2019, the Group has adopted Ind AS 116 Leases applicable to all contracts having lease components existing on 1 April 2019 using modified retrospective approach. This has resulted in recognising right of use asset and a corresponding lease liability of Rs.947.2 million as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from lease rent to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. Due to this change, profit before tax for the quarter and nine months ended 31 December 2019 is lower by Rs.14.0 million and Rs.25.9 million respectively. Consequent to adoption of Ind AS 116, there is no impact on retained earnings as on 1 April 2019 resulting in no restatement in results of comparative period. n n3) Pursuant to the Taxation Law (Amendment) Ordinance, 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on 20 September 2019 which is effective 1 April 2019, domestic companies have the option to pay corporate income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company and its subsidiaries incorporated in India have made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit. n n4) As per Ind AS 103, purchase consideration for acquisition of certain assets from AbbVie Inc.,USA. on 30 December 2019 has been allocated on a provisional basis. Going forward, the accounting for the acquired assets may change on the basis of additional information, if any. n n5) The Board of Directors at its meeting held on 7 February 2020 have declared an interim dividend of Rs. 22 (Rupees Twenty two only) per equity share (1100% on the face value of Rs. 2 each) for the financial year ended 2019-20. n n6) The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2019-04-01 2019-12-31 Unaudited Consolidated 62953700000.00 767500000.00 63721200000.00 16232600000.00 10946400000.00 -2673500000.00 11755700000.00 509100000.00 1717100000.00 14988900000.00 53476300000.00 10244900000.00 0.00 10244900000.00 1798700000.00 -1131500000.00 667200000.00 0.00 9577700000.00 0.00 0.00 0.00 0.00 9577700000.00 54100000.00 9631800000.00 9383000000.00 194700000.00 9447200000.00 184600000.00 239100000.00 2 78.48 78.48 0.00 0.00 78.48 78.48 Other expenses 4985200000.00 Other expenses 14988900000.00